Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation

N Engl J Med. 2018 May 17;378(20):1945-1947. doi: 10.1056/NEJMc1511490.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Histiocytic Sarcoma / diagnostic imaging
  • Histiocytic Sarcoma / drug therapy*
  • Histiocytic Sarcoma / genetics
  • Humans
  • MAP Kinase Kinase 1 / genetics*
  • Male
  • Metabolic Networks and Pathways
  • Middle Aged
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Mutation*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridones / therapeutic use*
  • Pyrimidinones / therapeutic use*

Substances

  • Protein Kinase Inhibitors
  • Pyridones
  • Pyrimidinones
  • trametinib
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human
  • Mitogen-Activated Protein Kinase Kinases